MIRA INFORM REPORT

 

 

Report Date :

18.07.2013

 

IDENTIFICATION DETAILS

 

Name :

ABBOTT HEALTHCARE PRIVATE LIMITED (w.e.f. 08.05.2002)

 

 

Formerly Known As :

KNOLL INTERNATIONAL PRIVATE LIMITED

 

 

Registered Office :

Unit No.4, Corporate Park, Sion, Trombay Road, Chembur, Mumbai – 400071, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

01.01.1997

 

 

Com. Reg. No.:

11-104834

 

 

Capital Investment / Paid-up Capital :

Rs. 21.560 Millions

 

 

CIN No.:

[Company Identification No.]

U24200MH1997PTC104834

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMK06799C

 

 

PAN No.:

[Permanent Account No.]

AAACK3935D

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer and Importer of Pharmaceutical Products.

 

 

No. of Employees :

2000 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (36)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 414600000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is a subsidiary of “Abbott Asia Holding Limited, UK”. It is an established company having a moderate track record.

 

The company has incurred huge loss from its operations during 2011.

 

However, trade relations are fair. Business is active. Payments are reported as slow but correct.

 

The company can be considered for business dealings with some caution. 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

  

 

 

INFORMATION PARTED BY (GENERAL DETAILS)

 

Name :

Mr. Suhas

Designation :

Accounts Department

Contact No.:

91-22-66754132

Date :

17.07.2013

 

 

LOCATIONS

 

Registered Office :

Unit No.4, Corporate Park, Sion, Trombay Road, Chembur, Mumbai – 400071, Maharashtra, India

Tel. No.:

91-22-67978888

Fax No.:

91-22-67978733/ 67978727

E-Mail :

webmaster@abbott.co.in

Website :

http://www.abbott.co.in

http://www.abbott-diabetescare.com 

http://www.abbottep.in

http://www.truecare.in

 

 

Factory :

Baddi, Himachal Pradesh, India

 

 

Branch Office 1 :

Diabetes Care

12, Corporate Park, Sion-Trombay Road, Mumbai - 400 071, Maharashtra, India

Tel No. :

91-22-67978831

Fax. No. :

91-22-67978921

 

 

Branch Office 2 :

Diagnostics

 Office No. 201, Everest Grande, Opposite Ahura Centre, Mahakali Road, Andheri (East), Mumbai – 400069, Maharashtra, India

Tel No. :

91-22-66754132 / 33

Fax. No. :

91-22-66790468

 

 

Branch Office 3 :

Nutritional Products

11th Floor , Hall Mark Plaza, Near Gurunanak Hospital, Bandra (East), Mumbai – 400 051, Maharashtra, India

Tel No. :

91-22-67566000

Fax. No. :

91-22-67576060

 

 

Branch Office 4  :

Vascular

Office Floor, The Surya, New Friends Colony, New Delhi - 110025 India

Tel. No.:

91-22-40530100

Fax No.:

91-22-40530198/ 199

 

 

Branch Office 5 :

Healthcare Solutions

1st floor, D Mart Building, Goregaon - Mulund Link Road, Mumbai – 400080, MaharashtraIndia

Tel No. :

91-22-39536666

Fax. No. :

91-22-39536845

 

 

Branch Office 6 :

True Care

1st Floor, Su Motors Complex, Model Town, Bal Rajeshwar Marg, Mulund (West), Mumbai – 400080, Maharashtra, India

Tel No. :

91-22-30781000

Fax. No. :

91-22-30781080

 

 

Branch Office 7  :

Medical Optics

The Masterpiece Lavel – 5, Golf Course Road, Sector - 54, Gurgaon - 122002, Haryana, India

 

 

Corporate Office :

D’ Mart Building, Goregaon Mulund Link Road, Mulund – West, Mumbai – 400080, Maharashtra, India

 

 

DIRECTORS

 

As on: 29.06.2012

 

Name :

Mr. Thomas Craig Freyman

Designation :

Director

Address :

912, Lake Street, Liberty Ville, Illinois-60048, USA

Date of Birth/Age :

08.09.1954

Date of Appointment :

02.05.2003

DIN No.:

00654517

 

 

Name :

Mr. Rajesh Upendra Pandya

Designation :

Director

Address :

B/23, 5th Floor, Sangam Apartment, 161 Versova Lane, Andheri (west), Mumbai – 400053, Maharashtra, India

Date of Birth/Age :

13.12.1963

Date of Appointment :

01.09.2005

DIN No.:

00096606

 

 

Name :

Mr. Sudarshan K Jain

Designation :

Director

Address :

Flat No. 101, 1st Floor, Jamunamahal Colony, Santacruz (East), Mumbai – 400055, Maharashtra, India

Date of Birth/Age :

06.06.1955

Qualification :

MBA

Date of Appointment :

25.07.2011

DIN No.:

00927487

 

 

KEY EXECUTIVES

 

Name :

Mr. Kiran M Ravi

Designation :

Secretary

Address :

2B,92, Kalpataru, J.V. Link Road, Andheri (East), Mumbai – 400059, Maharashtra, India

Date of Birth/Age :

18.08.1977

Date of Appointment :

01.09.2009

PAN No.:

AFLPM7387Q

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on: 29.06.2012

 

Names of Shareholders

 

No. of Shares

Abbott Asia Holding Limited, United Kingdom

 

2380998

Abbott Capital India Limited, Berkshire

 

2

Total

 

2381000

 

Allotees As on: 21.12.2012

 

Names of Allotees

 

No. of Shares

Abbott  Asia Holding Limited, United Kingdom

 

266930

Total

 

266930

 

 

Equity Share Break up (Percentage of Total Equity)

 

As on: 29.06.2012

 

Category

 

Percentage

Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others]

 

100.00

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Importer of Pharmaceutical Products.

 

 

Imports :

 

Products :

Raw Materials

Countries :

Germany

 

 

Terms :

 

Selling :

L/C, Cash and Credit

 

 

Purchasing :

L/C, Cash and Credit

 

 

GENERAL INFORMATION

 

Customers :

End Users and OEM’s

 

 

No. of Employees :

2000 (Approximately)

 

 

Bankers :

Standard Chartered Bank, 90 M G Road, Fort, Mumbai - 400001, Maharashtra, India

 

 

Facilities :

(Rs. In Millions)

SECURED LOAN

As on

31.12.2011

As on

31.12.2010

Loans taken for other fixed assets

1.746

0.000

Total

1.746

0.000

 

 

 

Banking Relations :

--

 

 

Financial Institution :

BNP Paribas, French Bank Building, Fort, Mumbai – 400001, Maharashtra, India

 

 

Auditors :

 

Name :

Deloitte Hanskins and sells

Chartered Accountants

Address :

Maker Towers, "E" Cuffe Parade, Mumbai 400005, Maharashtra, India

Tel. No.:

91-22-66679000

Fax No.:

91-22-66679100

PAN No.:

AACFD4815A

 

 

Holding Company :

Abbott Asia Holdings Limited, UK

 

 

Ultimate Holding Company:

Abbott Laboratories, USA

 

 

Fellow Subsidiaries :

·         Abbott Logistics BV, Netherlands

·         Abbott International Limited, USA

·         Abbott Laboratories International Company, USA

·         Abbott India Limited, India

·         Abbott GmBH and Company KG., Germany

·         Abbott Diagnostics GmBH, Germany

·         Abbott Laboratories (Singapore) Pte Limited., Singapore

·         Abbott Laboratories (M) Sdn. Bhd., Malaysia

·         Murex Biotech SA Pty Limited, South Africa

·         Abbott Vascular Devices Holland BV, Netherlands

·         Abbott Vascular, Ireland

·         Abbott Laboratories Limited, Hongkong

·         Abbott Vascular Japan Company Limited., Japan

·         Abbott Europe SA, Belgium

·         Abbott Vascular Solutions, Inc., USA

·         Abbott Cardiovascular Systems, Inc, USA

·         Abbott Australasia Pty. Limited, Australia

·         Abbott Laboratories SA, Dubai, UAE

·         Abbott Laboratories S.A., USA

·         Abbott Laboratories Services Corp. Taiwan

·         Abbott BV, Netherlands

·         Abbott Truecare Pharma Private Limited, India

·         Abbott France S.A.

·         Abbott UK

·         Abbott Medical Devices Trading (Shanghai) Company Limited.

 

CAPITAL STRUCTURE

 

After: 29.06.2012

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

29700000

Equity Shares

Rs.10/- each

Rs.297.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

2647930

Equity Shares

Rs.10/- each

Rs. 26.479 Millions

 

 

 

 

 

 

As on: 31.12.2011

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

29700000

Equity Shares

Rs.10/- each

Rs.297.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

2156000

Equity Shares

Rs.10/- each

Rs. 21.560 Millions

 

 

 

 

 

 

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.12.2011

31.12.2010

31.11.2009

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

21.560

5.000

5.000

2] Share Application Money

18352.100

107637.200

0.000

3] Reserves & Surplus

107802.280

329.344

1260.179

4] (Accumulated Losses)

(22523.094)

0.000

0.000

NETWORTH

103652.846

107971.544

1265.179

LOAN FUNDS

 

 

 

1] Secured Loans

1.746

0.000

0.000

2] Unsecured Loans

0.000

0.000

0.000

TOTAL BORROWING

1.746

0.000

0.000

DEFERRED TAX LIABILITIES

0.000

394.493

0.000

 

 

 

 

TOTAL

103654.592

108366.037

1265.179

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

155294.430

173280.749

336.160

Capital work-in-progress

1129.417

799.700

0.832

 

 

 

 

INVESTMENT

0.000

0.000

0.000

DEFERREX TAX ASSETS

0.000

0.000

35.986

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

3552.286

2418.480

465.524

 

Sundry Debtors

2384.010

2006.659

508.289

 

Cash & Bank Balances

8968.044

5727.870

804.495

 

Other Current Assets

80.654

21.202

1.539

 

Loans & Advances

1481.383

1073.970

191.180

Total Current Assets

16466.377

11248.181

1971.027

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

1206.930

868.073

656.814

 

Other Current Liabilities

66765.060

75045.049

388.392

 

Provisions

1263.642

1049.471

33.620

Total Current Liabilities

69235.632

76962.593

1078.826

Net Current Assets

(52769.255)

(65714.412)

892.201

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

103654.592

108366.037

1265.179

 

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.12.2011

31.12.2010

31.11.2009

 

SALES

 

 

 

 

 

Sales

27318.849

12134.402

4116.374

 

 

Other Income

NA

NA

NA

 

 

TOTAL                                    

NA

NA

NA

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Office Expenses

 

 

Administrative Expenses

 

 

 

 

 

Advertising Expenses

 

 

 

 

 

TOTAL                                    

NA

NA

NA

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX                                     

(23077.915)

(310.258)

221.708

 

 

 

 

 

Less

TAX                                                                 

(407.242)

620.577

85.250

 

 

 

 

 

 

PROFIT / (LOSS) AFTER TAX                          

(22670.673)

(930.835)

136.458

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

147.579

1078.414

941.956

 

 

 

 

 

 

BALANCE CARRIED TO THE B/S

(22523.094)

147.579

1078.414

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Reimbursement of Expenses

NA

NA

2.553

 

TOTAL EARNINGS

NA

NA

2.553

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Finished Goods

NA

2077.237

 

 

Stores & Spares

 

NA

13.089

 

 

Capital Goods

 

NA

117.329

 

TOTAL IMPORTS

47096.420

NA

2207.655

 

 

 

 

 

 

Earnings Per Share (Rs.)

(9521.49)

(1861.67)

NA

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.12.2011

31.12.2010

31.11.2009

Net Profit Margin

(PBT/Sales)

(%)

(84.48)

(2.56)

5.39

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

(13.43)

(0.17)

9.48

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

(0.22)

(0.00)

0.18

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.00

0.00

0.00

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

0.23

0.15

1.82

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

Yes

10]

Designation of contact person

Yes

11]

Turnover of firm for last two years

Yes

12]

Profitability for last two years

Yes

13]

Reasons for variation <> 20%

---------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

Yes

20]

Export / Import details (if applicable)

Yes

21]

Market information

---------

22]

Litigations that the firm / promoter involved in

---------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

--

26]

Buyer visit details

--

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

CURRENT MATURITIES OF LONG TERM DEBT : NOT AVAILABLE

 

 

NOTE :

 

Registered Office Address of the company has been shifted from Unit No.3 and 4 ,Corporate Park, Sion - Trombay Road, Chembur, Mumbai – 400071, Maharashtra, India to present w.e.f. 13.07.2009

 

 

PRESS RELEASE :

 

Abbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India

 

Abbott Park, Illinois (NYSE: ABT) — Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.

 

Throughout the past decade, Abbott has established a leading presence in emerging markets – today, more than 20 percent of the company's total sales are generated in these growing economies.

 

"The acquisition of Piramal's Healthcare Solutions business further strengthens Abbott's growing presence in emerging markets," said Miles D. White, chairman and chief executive officer, Abbott. "Piramal's portfolio of well-known, trusted products has served patients in India for decades. Combined with existing product offerings, Abbott is uniquely positioned to meet the needs of one of the world's fastest-growing pharmaceutical markets."

 

India's rapid pharmaceutical market growth is being driven largely by branded generics. The market will generate nearly $8 billion in pharmaceutical sales this year, a number that is expected to more than double by 2015. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020.

 

Piramal's Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience.

 

The Healthcare Solutions business will operate as a separate business unit, reporting into Abbott's newly-created Established Products Division (EPD), which was formed to focus on branded generics, maximizing the opportunity in emerging markets. The business will continue to be led by its current India-based management team.

 

"Piramal's proven business model in India and experienced local leadership team, combined with the global resources of Abbott, will allow us to build upon Piramal's commitment to quality and service," said Michael J. Warmuth, senior vice president, Established Products, Pharmaceutical Products Group, Abbott.

 

Abbott now employs approximately 10,000 people across all of its businesses in India.

 

Abbott, through a wholly-owned subsidiary, purchased the assets of Piramal's Healthcare Solutions business for a $2.2 billion up-front payment with additional payments of $400 million annually for the next four years, beginning in 2011. This transaction will not impact Abbott's ongoing earnings per share guidance in 2010.

 

About Abbott

 

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

 

Abbott Forward-Looking Statement

 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in Item 1A, "Risk Factors," to our Quarterly Report on Securities and Exchange Commission Form 10-Q for the period ended March 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

 

 

FIXED ASSETS :

 

  • Leasehold Improvement
  • Machinery and Equipments
  • Vehicles
  • Furniture, Fittings and Office Equipments
  • Goodwill

 

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 59.36

UK Pound

1

Rs. 89.69

Euro

1

Rs. 77.99

 

 

INFORMATION DETAILS

 

Information Gathered by :

PLK

 

 

Report Prepared by :

NIS

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

4

OPERATING SCALE

1~10

4

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

4

--PROFITABILIRY

1~10

3

--LIQUIDITY

1~10

4

--LEVERAGE

1~10

4

--RESERVES

1~10

4

--CREDIT LINES

1~10

4

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

36

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.